Managing chronic nonmalignant pain with continuous intrathecal morphine.
One alternative to traditional treatment modalities for chronic pain is continuous intrathecal administration of morphine via an implanted pump. However, relatively little is known about the benefits and long-term complications of this therapy for chronic nonmalignant pain. The purpose of this study was to describe patient responses to continuous intrathecal morphine over the course of one year with respect to morphine dosage used, complications and subjective assessments of pain. Data were obtained from twelve patients who completed one year of therapy. After one year, a 42% reduction in pain as measured by the McGill pain questionnaire had occurred (p < .01). A similar 41% reduction in pain was also present based on the Verbal Descriptor Scale (p < .01). A 35% reduction in the perceived hardship of pain was present (p < .01) accompanied by anecdotal comments that an improvement in the ability to manage activities of daily living had occurred. One patient was able to return to work. A statistically nonsignificant increase in the mean daily dosage of morphine occurred and few long-term adverse effects were present. Complications of implantation occurred in 33.3% of the patients and were successfully managed without discontinuing therapy. In selected patients with chronic pain, intrathecal administration of morphine via an implanted pump can reduce pain with minimal long-term adverse effects or complications.